Physician profile
Sara Blitenthal
NPI 1801671706
$1,549.98
in general payments reported to CMS, 2019-2025
26 companies · $965 in 2025
The $965 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $585 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.99 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.37 | 2024-2025 | |
| Lilly USA, LLC | $200.09 | 2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $143.76 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $123.94 | 2024-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $107.16 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $100.09 | 2024-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $94.86 | 2024-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.49 | 2025 | Caplyta |
| Exact Sciences Corporation | $48.33 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $47.86 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Argenx US, INC. | $42.32 | 2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $35.21 | 2025 | |
| Vanda Pharmaceuticals INC. | $24.50 | 2025 | Fanapt |
| Ani Pharmaceuticals, INC. | $23.35 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $22.67 | 2025 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.86 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.67 | 2025 | Voquezna |
| Avadel Cns Pharmaceuticals, LLC | $21.13 | 2025 | Lumryz |
| Lundbeck LLC | $20.13 | 2025 | Vyepti |
| Novo Nordisk INC | $19.99 | 2024 | |
| Genentech USA, INC. | $19.93 | 2025 | Ocrevus Zunovo |
| Corcept Therapeutics | $18.83 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $18.03 | 2025 | Symbravo |
| Ucb, INC. | $17.86 | 2025 | Fintepla |
| Sage Therapeutics, LLC | $16.13 | 2025 | Zurzuvae |
| Alkermes, INC. | $15.42 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Blitenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.